NEW YORK ( TheStreet) -- Clinical trials with a tight timeline for data release provide an excellent way for traders to profit from the anticipatory run-up in stock price, while also managing the risk of getting caught when data are released.
Catalyst Pharmaceutical Partners (CPRX) demonstrated nicely last week the benefit of knowing when to exit a run-up trade before clinical trial data is announced. Catalyst told us to expect results from a study of its cocaine addiction drug during the first half of November. This gave traders ample time to play a run-up in Catalyst's stock price from 67 cents per share to a peak of $2.27 per share before exiting positions by Nov. 1. A week later, Catalyst announced the failure of its cocaine addiction drug, sending the company's stock price cratering down to around 40 cents per share.
Celsion (CLSN) is a new run-up trading opportunity. Last Friday, the company announced the 380th progression event in its pivotal Thermodox liver cancer trial. This event triggers the data collection and analysis process by the study's independent monitors. Celsion said it expects to announce top-line results from the Thermodox study in January 2013.
The run-up trade in Celsion is already underway, with shares up 22% to $5.34 since Friday.Celsion's market cap is only $187 million so positive results from the Thermodox study are likely to send the company's stock price soaring. Shares hit a recent high of $6.09 in late September. Barring a major market correction, I expect Celsion shares to continue higher as the January release of the Thermodox data nears. Cautious run-up traders should exit positions before the end of the year to avoid being caught long when the Thermodox results are announced. If you're thinking about holding a position through the results, I recommend taking profits on your initial trade and keeping "free shares" only. Those who like to trade using options can roll run-up profits into Calls that expire after data are expected. Because we don't know exactly when in January Celsion will release Thermodox data, it's safest to use your profits to buy calls that expire in February 2013. Messier has no position in Celsion.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV